As the world’s most comprehensive health care company, Johnson & Johnson touches the lives of millions of people every day by bringing forward transformational products in pharmaceuticals, consumer health and medical devices & diagnostics. With a strong vision, a culture of caring, and the resources to invest in the future, we are committed to improving health and well-being for people all over the world.
Janssen, the pharmaceutical companies of Johnson & Johnson, is advancing this vision through a focus on the research and development of state-of-the-art pharmaceutical medicines. We work to identify the best science, at every stage of innovation and wherever it exists in the world, and apply our internal expertise and industry-leading operational capabilities to bring solutions to the people who need them.
The medical challenges we are trying to solve today – diabetes, cancer, Alzheimer’s disease – are extremely complex, and we know that no one company or organization can address these challenges alone. That is why partnerships are essential to the success of our company, our industry and to the millions of patients who are waiting for new solutions.
As the Business Development group within Janssen, my team has a long tradition of fostering successful partnerships. We work to build each collaboration on a shared vision with well-defined and agreed-upon goals and objectives. We value open communication, sound implementation, and a solid relationship with our partners built on trust, recognition and mutual respect.
We are now taking our commitment to innovation and collaboration a step further, by changing our name and aligning our brand identity with Johnson & Johnson Innovation. As Johnson & Johnson Innovation – Janssen Business Development, we will work with our colleagues at the J&J Innovation Centers, J-Labs, JJDC and Janssen to advance innovation at every stage and to provide a continuum of interaction for partners.
Our Janssen Business Development team is primarily focused on the near-term and on collaborations with established biotech and pharmaceutical companies. We also are accountable for all mergers and acquisitions and for any deal, regardless of the source, for an asset that is late stage, ie post clinical proof-of-concept. If you would like to learn more about collaborating with Janssen, please reach out to me or the following members of the team.
Tom Heyman, Head, Janssen Business Development
Robert Wills, Vice President Alliance Management